Your browser doesn't support javascript.
loading
Current status and updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland.
Samaras, Panagiotis; Bargetzi, Mario; Betticher, Daniel C; Duchosal, Michel A; Heim, Dominik; Hess, Urs; Ketterer, Nicolas; Lerch, Erika; Matthes, Thomas; Mey, Ulrich; Pabst, Thomas; Taverna, Christian; Zander, Thilo; Renner, Christoph.
Afiliação
  • Samaras P; Department of Medical Oncology, University Hospital Zurich, Switzerland.
  • Bargetzi M; Centre of Oncology/Haematology and Transfusion Medicine, Cantonal Hospital Aarau, Switzerland.
  • Betticher DC; Clinics of Medical Oncology, HFR Fribourg Cantonal Hospital, Switzerland.
  • Duchosal MA; Service and Central Laboratory of Heamatology, University Hospital of Lausanne, Switzerland.
  • Heim D; Department of Haematology, University Hospital Basel, Switzerland.
  • Hess U; Division of Oncology/Haematology, Cantonal Hospital St. Gallen, Switzerland.
  • Ketterer N; Clinic Bois-Cerf, Onco-haematology, Lausanne, Switzerland.
  • Lerch E; Oncology Institute of Southern Switzerland (IOSI), Ospedale San Giovanni, Bellinzona, Switzerland.
  • Matthes T; Division of Haematology, University Hospital Geneva, Switzerland.
  • Mey U; Medical Oncology and Haematology, Cantonal Hospital Graubuenden, Chur, Switzerland.
  • Pabst T; Department of Medical Oncology, University Hospital of Berne, Switzerland.
  • Taverna C; Oncology/Haematology, Cantonal Hospital Münsterlingen, Switzerland.
  • Zander T; Department of Medical Oncology, Cantonal Hospital Lucerne, Switzerland.
  • Renner C; Oncology Centre Hirslanden & Zurich, Switzerland.
Swiss Med Wkly ; 145: w14100, 2015.
Article em En | MEDLINE | ID: mdl-25999239
The availability of drugs such as thalidomide, bortezomib and lenalidomide changed the landscape in myeloma treatment and has extended the median survival up to 10 years with a substantial improvement in quality of life. This development prompted a Swiss expert panel to re-evaluate the current status and formulate updated clinical recommendations for the diagnosis and treatment of plasma cell myeloma. These recommendations should help clinicians in their decision making to achieve the best outcome based on currently available data.
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Mieloma Múltiplo Tipo de estudo: Diagnostic_studies / Guideline / Prognostic_studies Limite: Humans País/Região como assunto: Europa Idioma: En Revista: Swiss Med Wkly Assunto da revista: MEDICINA Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Suíça
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Mieloma Múltiplo Tipo de estudo: Diagnostic_studies / Guideline / Prognostic_studies Limite: Humans País/Região como assunto: Europa Idioma: En Revista: Swiss Med Wkly Assunto da revista: MEDICINA Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Suíça